Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

• ClinicalTrials.gov Identifier: NCT03732768
• Recruitment Status: Recruiting
• First Posted: November 7, 2018
• Last Update Posted: January 19, 2023
• Sponsor: Oncoinvent AS
• Information provided by (Responsible Party): Oncoinvent AS

Study Description

Brief Summary:

RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose Limiting Toxicicities (which will stop the dose escalation), this will be the recommended dose for further exploration. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first).

In the expansion cohort the subject will receive the recommended dose. The expansion cohort will be conducted at 4 sites. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first).

Condition or disease	Intervention/treatment	Phase
Peritoneal Carcinomatosis; Ovarian Cancer	Drug: Radspherin	Phase 1

Detailed Description:

The maximum number of subjects enrolled in this study is 49.

The following number of subjects will be recruited in the different cohorts:

• Dose escalation cohorts: 3 - 24 Subjects
• Expansion cohort: Up to 25 Subjects

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 49 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: 3+3 dose escalation study followed by an expansion cohort.
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following CRS
• Actual Study Start Date: June 8, 2020
• Estimated Primary Completion Date: August 2025
• Estimated Study Completion Date: August 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Radspherin	Drug: Radspherin; Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.

Outcome Measures

Primary Outcome Measures :

1. Number of participants with Dose Limiting Toxicities as assessed by CTCAE v5.0. [ Time Frame: 24 months ]
   To investigate safety and toxicity of Radspherin®
2. Maximum Tolerated Dose (MTD) [ Time Frame: 21 days ]
   To determine the MTD of Radspherin®, among the four suggested doses 1, 2, 4 and 7 MBq, as a single intraperitoneal (IP) injection and two repeated IP injections following cytoreductive surgery (CRS)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Gender identity (Ovarian Cancer)
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Able and willing to provide written informed consent and to comply with the clinical study protocol
2. Age ≥ 18 years
3. Histologically confirmed epithelial ovarian, fallopian tube and primary peritoneal carcinoma
4. Platinum sensitive recurrences of ovarian carcinoma who are eligible for debulking surgery to R0.
5. AEs recovered to at least grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy at time of first administration of Radspherin®
6. ECOG Performance Status Score of 0 - 1

7. Adequate renal function

   • Creatinine ≤ 1.8 mg/dl (159 μmol/l) and
   • calculated creatinine clearance using the Cockcroft-Gault formula ≥ 45 ml/min, or
   • measured creatinine clearance ≥ 45 ml/min

8. Adequate hepatic function

   • Serum bilirubin <1.5 x upper limit of normal (ULN)
   • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN

9. Adequate bone marrow function:

   • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/l
   • Platelets ≥ 100 x 10^9/l
   • Haemoglobin ≥ 9 g/dL
10. Adequate coagulation tests: INR ≤ 1.5 x ULN
11. For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment
12. For females of childbearing potential who have a male partner: agreement to use two adequate methods of contraception (e.g. barrier, intrauterine device, hormonal implants, combined oral contraceptives or vasectomized partner), during the treatment period and for at least 3 months after the last dose of IMP.

Exclusion Criteria:

1. Neuroendocrine tumors, or non-epithelial ovarian cancers (e.g. germ cell tumors, Sex-cord tumors)
2. Tumors of borderline malignancy
3. Other synchronous visceral metastatic lesions, symptomatic CNS metastases. Metastatic lymph nodes are acceptable, except thoracic lymph nodes.
4. Pregnant or lactating (nursing) women
5. Active infections requiring antibiotics, and/or physician monitoring or recurrent fever >38.0 ⁰C associated with a clinical diagnosis of active infection
6. Active liver disease with positive serology for active hepatitis B, hepatitis C or known HIV
7. Administration of an investigational medicinal product within 28 days, or at least 5 times the half-life, prior to enrolment
8. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the last study treatment
9. Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cervical cancer in situ or in situ stage 1 synchronous endometrial cancer)
10. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease
11. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise the safety of the subjects or interfere with the evaluation of the safety of the IMP
12. In the Investigator's opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent
13. Treatment with bevacizumab (Avastin®) within 5 weeks prior to CRS
14. Known hypersensitivity to any of the excipients in the study drug
15. Persons who have been placed in an institution under an official or judicial order
16. Persons who are dependent on the sponsor financially must be excluded from participation
17. Persons with active SARS-CoV-2 infection must be excluded from participation

Contacts and Locations

Contacts

Contact: Anne-Kirsti Aksnes, PhD; +47 22 18 33 05; aksnes@oncoinvent.com

Contact: Trine J Gjertsen; +47 22 18 33 05; gjertsen@oncoinvent.com

Locations

Belgium

UZ Leuven; Recruiting

Leuven, Belgium, 3000

Contact: Els Van Nieuwenhuysen, MD

Norway

The Norwegian Radiumhospital; Recruiting

Oslo, Norway

Contact: Yun Wang, MD

Spain

Clínica Universidad de Navarra; Recruiting

Madrid, Spain

Contact: Luis M Chiva, MD, PhD

Clínica Universidad de Navarra; Recruiting

Pamplona, Spain

Contact: Luis M Chiva, MD, PhD

Sponsors and Collaborators

Oncoinvent AS

More Information

• Responsible Party: Oncoinvent AS
• ClinicalTrials.gov Identifier: NCT03732768
• Other Study ID Numbers: RAD-18-001; 2018-002802-29 ( EudraCT Number )
• First Posted: November 7, 2018
• Last Update Posted: January 19, 2023
• Last Verified: January 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma; Peritoneal Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Endocrine System Diseases; Gonadal Disorders; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Abdominal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Peritoneal Diseases